ReviewFrontiers in immunology2026
Research progress on traditional Chinese medicine-assisted immune checkpoint inhibitors therapy for solid tumors.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune checkpoint inhibitors (ICIs) represent a promising approach in tumor therapy. However, when applied to solid tumors-the predominant form of tumors-their efficacy is often constrained by the distinctive tumor microenvironment, yielding low response rates and resistance. Additionally, treatment with ICIs commonly leads to immune-related adverse events (irAEs). These challenges have restricted the broader clinical application of ICIs, underscoring the need for strategies that can enhance their antitumor effects while maintaining a favorable safety profile. Traditional Chinese medicine (TCM) is characterized by holistic regulation and has the therapeutic advantages of multi-level, multi-target and low toxicity. In recent years, it has shown great potential in addressing ICIs-related limitations. This review systematically summarizes current advances in the combined use of TCM and ICIs for solid tumors, aiming to offer new perspectives for incorporating TCM into future cancer treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.